Analyst picks & changes

Gensia Pharmaceuticals Inc.


Analysts responded positively to GNSA's announcement that enrollment in its latest Phase III study of Protara was stopped by the San Diego company's independent panel after 2,500 patients had been analyzed (see BioCentury, Aug. 15).

Hambrecht & Quist analyst Alex Zisson upgraded the stock from

Read the full 492 word article

How to gain access

Continue reading with a
two-week free trial.